Glycoprotein, E.g., Mucins, Proteoglycans, Etc. Patents (Class 530/395)
-
Publication number: 20140350370Abstract: The disclosure provides a ligand that competes with glucose for binding the protein Concanavalin A (ConA) and competitive binding assays incorporating the ligand. The competing ligand binds to the primary and part or all of the extended binding sites of Concanavalin A. These and other aspects of the disclosure are useful for glucose monitoring (e.g., continuous glucose monitoring (CGM)).Type: ApplicationFiled: April 8, 2014Publication date: November 27, 2014Applicant: THE TEXAS A&M UNIVERSITY SYSTEMInventors: Brian M. Cummins, Gerard L. Coté
-
Patent number: 8895018Abstract: Methods are provided for the treatment of subjects with cognitive or neuropsychiatric impairment induced by substance addiction and for increasing cognitive function in a subject with substance addiction. In some embodiments, the methods include administering to the subject a therapeutically effective amount of a major histocompatibility complex (MHC) molecule including covalently linked first, second, and third domains; wherein the first domain is an MHC class II ?1 domain and the second domain is an MHC class II ?1 domain; or wherein the first domain is an MHC class I ?1 domain and the second domain is an MHC class I ?2 domain; and wherein the third domain is covalently linked to the first domain and comprises an antigen of the central or peripheral nervous system.Type: GrantFiled: June 21, 2013Date of Patent: November 25, 2014Assignees: Oregon Health & Science University, The United States of America as represented by the Department of Veteran AffairsInventors: Arthur A. Vandenbark, Gregory G. Burrows
-
Patent number: 8895516Abstract: Saccharide-protein conjugates having a new type of linker are described. The conjugates comprising the new linker are prepared from modified saccharides comprising a moiety of the formula (I): -A-N(R1)-L-M wherein: A is a bond, —C(O)— or —OC(O)—; R1 is selected from H or C1-C6 alkyl; L is a C1-C12 alkylene group; and M is a masked aldehyde group. The new linker is especially useful for preparing conjugates of Neisseria meningitidis serogroup A saccharide. Conjugates having this new linker have improved immunogenicity compared to other types of conjugates.Type: GrantFiled: September 1, 2003Date of Patent: November 25, 2014Assignee: Novartis AGInventors: Aldo Giannozzi, Giovanni Averani, Francesco Norelli, Paolo Costantino
-
Patent number: 8895507Abstract: Soluble proteins, e.g. Hevin, can trigger synapse formation; and other soluble proteins, e.g. SPARC antagonize this activity. Such proteins are synthesized in vitro and in vivo by astrocytes. Methods are provided for protecting or treating an individual suffering from adverse effects of deficits in synaptogenesis, or from undesirably active synaptogenesis.Type: GrantFiled: April 16, 2008Date of Patent: November 25, 2014Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ben A. Barres, Cagla Eroglu
-
Patent number: 8895027Abstract: The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions.Type: GrantFiled: February 2, 2012Date of Patent: November 25, 2014Assignees: Merial Limited, Centre National de la Recherche Scientifique, Institut Gustave Roussy, Universite Paris-SudInventors: Hervé Poulet, Thierry Heidmann
-
Publication number: 20140342453Abstract: A nucleotide construct comprising a nucleotide sequence that forms a stem and a loop, wherein the loop comprises a nucleotide sequence that modulates expression of a target, wherein the stem comprises a nucleotide sequence that modulates expression of a target, and wherein the target modulated by the nucleotide sequence in the loop and the target modulated by the nucleotide sequence in the stem may be the same or different. Vectors, methods of regulating target expression, methods of providing a cell, and methods of treating conditions comprising the nucleotide sequence are also disclosed.Type: ApplicationFiled: August 5, 2014Publication date: November 20, 2014Inventors: John Shanklin, Tam Huu Nguyen
-
Publication number: 20140336366Abstract: Provided herein are prokaryotic cells capable of producing bioconjugates comprising glycosylated proteins. Also provided herein are compositions comprising such bioconjugates and/or comprising the saccharide moieties of such bioconjugates, as well as methods of vaccinating subjects using such compositions.Type: ApplicationFiled: September 6, 2012Publication date: November 13, 2014Applicant: GLYCOVAXYN AGInventor: Amirreza Faridmoayer
-
Publication number: 20140335192Abstract: Provided are compositions for the delivery of biomolecules, such as nucleic acids into target cells, and methods of making and using same. The compositions comprise nucleic acid delivery complexes that include a nucleic acid, such as an RNA interfering agent, an RNA neutralization domain, a double stranded RNA binding domain, and a protein transduction domain.Type: ApplicationFiled: May 9, 2014Publication date: November 13, 2014Inventors: Gary H. WARD, Curt W. BRADSHAW
-
Publication number: 20140335126Abstract: The present invention relates, in general, to human immunodeficiency virus (HIV), and in particular to a vaccine for HIV-1 and to methods of making and using same.Type: ApplicationFiled: December 5, 2012Publication date: November 13, 2014Inventors: Barton F. Haynes, Huaxin Liao, Jerome Kim, Nelson Michael, Susan B. Zolla-Pazner
-
Patent number: 8883445Abstract: The present invention provides genetically engineered strains of methylotrophic yeast including Pichia and especially Pichia pastoris capable of producing proteins with reduced or modified glycosylation. Methods of producing glycoproteins with reduced and/or modified glycosylation using such genetically engineered strains of Pichia are also provided. Vectors, which comprise coding sequences for ?-1,2-mannosidase I, glucosidase II, GlcNAc-tranferase I and mannosidase II or comprising OCH1 disrupting sequence, for transforming methylotrophic yeasts are contemplated by the present invention. Kit for providing the comtemplated vectors are also included in this invention.Type: GrantFiled: July 13, 2007Date of Patent: November 11, 2014Assignees: Research Corporation Technologies, Inc., Universiteit Gent, Vib, VZWInventors: Roland Contreras, Nico L. M. Callewaert, Steven C. J. Geysens, Vladimir Kaigorodov, Vervecken Wouter
-
Publication number: 20140328883Abstract: The invention relates to methods for preparing crosslinked polyelectrolytes, in particular crosslinked polyelectrolytes multilayer films. The invention also relates to a method of coating a surface, and the obtained coated article.Type: ApplicationFiled: December 30, 2013Publication date: November 6, 2014Inventors: Catherine Picart, Jean-Claude Voegel, Benoit Frisch, Pierre Schaaf, Gero Decher, Frederic Cuisinier
-
Publication number: 20140329998Abstract: The invention provides a process for the reductive amination of a carbonyl group at the reducing terminus of a polysaccharide, wherein the reductive amination is carried out at a pH between 4 and 5. The invention also provides a process for preparing a conjugate of a polysaccharide and a carrier molecule, comprising the steps of: (a) coupling the polysaccharide to a linker, to form a polysaccharide-linker compound in which the free terminus of the linker is an ester group; and (b) reacting the ester group with a primary amine group in the carrier molecule, to form a polysaccharide-linker-carrier molecule conjugate in which the linker is coupled to the carrier molecule via an amide linkage. The invention also provides a process for reducing contamination of a polysaccharide-linker compound with unreacted linker, comprising a step of precipitating unreacted linker under aqueous conditions at a pH of less than 5.Type: ApplicationFiled: September 14, 2012Publication date: November 6, 2014Applicant: NOVARTIS AGInventors: Allan James Saul, Francesca Micoli
-
Patent number: 8877896Abstract: Systems, compositions, methods, and kits for identifying potential therapeutic agents for treatment of complement based ocular diseases are provided herein. The methods and kits include a complement component 3 (C3) protein or derivative that is contacted to ocular cells or tissue. Another embodiment of the invention herein provides for diagnosis and/or prognosis of a complement-associated ocular disease. Compositions, methods and kits for regulating or treating a complement-related condition using at least one of CD46 protein, CD55 protein, and a recombinant chimeric soluble terminator of activated complement (STAC) protein or source of the STAC protein. The STAC protein includes an amino acid sequence including at least two of an amino acid sequence of a CD59 protein, an amino acid sequence derived from a CD46 protein, and an amino acid sequence derived from a CD55 protein, optionally further comprising a linker to connect amino acid sequences.Type: GrantFiled: December 3, 2012Date of Patent: November 4, 2014Assignee: Tufts UniversityInventors: Rajendra Kumar-Singh, Siobhan M. Cashman, John Harry Sweigard
-
Publication number: 20140323688Abstract: This invention provides novel reagents for cyanating polysaccharides in aqueous or part aqueous solutions so that they may be covalently linked to proteins either directly or through a spacer. These reagents include 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT), 1-cyano-imidazole (1-CI), 1-cyanobenzotriazole (1-CBT), or 2-cyanopyridazine-3(2H)one (2-CPO), or a functional derivative or modification thereof. The examples illustrate the use of these reagents with a variety of polysaccharides and proteins showing that the methods are generally applicable.Type: ApplicationFiled: June 24, 2014Publication date: October 30, 2014Inventor: Andrew Lees
-
Publication number: 20140322132Abstract: Provided are fragments of human p97 (melanotransferrin) polypeptides having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, conjugates comprising said p97 fragments, and related methods of use thereof, for instance, to facilitate delivery of therapeutic or diagnostic agents across the BBB.Type: ApplicationFiled: March 13, 2014Publication date: October 30, 2014Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
-
Publication number: 20140323699Abstract: The present invention provides a method for labeling or detecting a protein with certain glycosyl groups. The methods are particularly useful for detecting cancer cells comprising the detected glycosyl groups. The present invention further provides labeling agents and detection agents, labeled proteins and mixtures, and kits and arrays thereof.Type: ApplicationFiled: January 3, 2014Publication date: October 30, 2014Applicant: California Institute of TechnologyInventors: Linda C. Hsieh-Wilson, Wen Yi, Jean-Luc Chaubard
-
Publication number: 20140323324Abstract: The purpose of the present invention is to develop: a method for selectively separating a glycoprotein derived from the central nervous system from a body fluid or a central nervous system cell; and a method for searching for an index marker for central nervous system diseases, which utilizes the aforementioned method. A protein derived from the central nervous system, which occurs in a trace amount in a body fluid or a central nervous system cell, can be selectively enriched by a two-stage separation procedure comprising removing a glycoprotein having sialic acid at a non-reducing terminal thereof from the body fluid or the central nervous system cell and then separating a glycoprotein having N-acetylglucosamine at a non-reducing terminal thereof.Type: ApplicationFiled: December 16, 2011Publication date: October 30, 2014Applicant: National Institute of Advanced Industrial Science and TechnologyInventors: Hisashi Narimatsu, Jun Hirabayashi, Atsushi Kuno, Hideki Matsuzaki, Yuzuru Ikehara, Hiromi Ito, Yasuhiro Hashimoto, Keiro Shirotani, Satoshi Futakawa, Hajime Arai, Masakazu Miyajima, Kazuo Fujihara
-
Publication number: 20140323700Abstract: The present invention relates to recombinant N-glycosylated proteins, comprising one or more introduced N-glycosylated optimized amino acid sequence(s), nucleic acids encoding these proteins as well as corresponding vectors and host cells. In addition, the present invention is directed to the use of said proteins, nucleic acids, vectors and host cells for preparing medicaments. Furthermore, the present invention provides methods for producing said proteins.Type: ApplicationFiled: February 6, 2014Publication date: October 30, 2014Applicant: ETH ZÜRICHInventors: Markus Aebi, Michael Kowarik, Umesh Ahuja
-
Publication number: 20140316108Abstract: A coating of a random copolymer of acrylamide and a second monomer, e.g. glycidoxylmethacrylate, for a silica surface is described. The coating is applied to chromatographic support structures having silica based surfaces. The coating is functionalized to produce protein chromatography matrices that are particularly useful for extracting trace amounts of biomarker molecules from biological samples.Type: ApplicationFiled: November 1, 2012Publication date: October 23, 2014Inventors: Mary J. Wirth, Yirmin Hua, Zhaorui Zhang
-
Publication number: 20140315185Abstract: Methods for improving the functionality and/or fertility of sperm, for example, by enhancing motility and extending the lifespan of sperm in the FRT, by adding functional molecules of interest attached to a membrane anchoring agent-PEG conjugate to the surface of the sperm are provided. Such methods may be used in AI to reduce the number of sperm needed for insemination and to improve conception rates.Type: ApplicationFiled: August 8, 2012Publication date: October 23, 2014Applicant: ANDROGENIX LTD.Inventors: Bridget Lee Dicker, Jiwon Hong, Keith Hudson, Shakeela Nathalia Jayasinghe
-
Publication number: 20140315826Abstract: Polymer conjugates containing a C1-inhibitor having at least one substantially non-antigenic polymer covalently attached to the C1-inhibitor via glycan group of the C1 inhibitor is provided. In addition, methods of making the conjugates as well as methods of treatment using the conjugate of the present invention are also provided.Type: ApplicationFiled: March 15, 2013Publication date: October 23, 2014Applicant: Belrose Pharma, Inc.Inventors: Hong Zhao, Karen Yang
-
Publication number: 20140314813Abstract: A novel lipoteichoic acid (LTA) was isolated from C. difficile, the structure of which is illustrated below wherein n is an integer between 1 and 20, R3 and R4 are independently selected from C 14:0, C 16:0, C 16:1, C 18:0 or C18:1 fatty acid or any combination thereof wherein one of COR3 or COR4 may be replaced by H. Further described are conjugates comprising the novel LTA and vaccines produced using the isolated LTA and the LTA conjugates. The invention also encompasses methods of conferring immunity against C. difficile comprising administering a vaccine of the invention, and methods of detecting C. difficile using the isolated LTA of the invention.Type: ApplicationFiled: November 16, 2012Publication date: October 23, 2014Applicant: National Research Council of CanadaInventors: Christopher Reid, Susan M. Logan, Evguenii Vinogradov, Andrew Cox, Jean-Robert Brisson
-
Publication number: 20140315806Abstract: The present invention relates to veterinary decorin compositions and methods of their production.Type: ApplicationFiled: April 22, 2014Publication date: October 23, 2014Applicant: CATALENT PHARMA SOLUTIONS, LLCInventor: Gregory T. Bleck
-
Publication number: 20140315800Abstract: [Problem] To provide a glycosylated polypeptide having affinity to somatostatin receptors and, compared to somatostatins, having improved in-blood stability. [Solution] The glycosylated polypeptide is characterized by at least two amino acids in a somatostatin or an analogue thereof being replaced by glycosylated amino acids.Type: ApplicationFiled: September 3, 2012Publication date: October 23, 2014Applicant: Glytech, Inc.Inventors: Hirofumi Ochiai, Taiji Shimoda, Kazuhiro Fukae, Masatoshi Maeda, Keisuke Tazuru, Kenta Yoshida
-
Publication number: 20140314797Abstract: Lower eukaryotic host cells have been engineered to produce glycoprotein having at least one terminal ?-galactosyl epitope. The glycoproteins are useful for the production of highly antigenic glycoprotein compositions with advantages for the production of vaccines.Type: ApplicationFiled: July 2, 2014Publication date: October 23, 2014Inventors: Natarajan Sethuraman, Robert C. Davidson, Terrance A. Stadheim, Stefan Wildt
-
Publication number: 20140315212Abstract: The present invention relates to a method for the purification, concentration and identification of glycosylphosphatidylinositol anchored proteins (GPI-APs) from a biological sample (cells, tissues and/or blood/serum) in a patient or subject, including a human patient or subject. A new method to separate GPI-anchored glycoproteins, a class of glycoproteins found in all animal cells and fluids including serum, from other glycoproteins and proteins for the purpose of identifying potential biomarkers for various diseases, including cancer, especially breast cancer, vaginal cancer, endometrial cancer, uterine cancer, cervical cancer, pancreatic cancer and prostate cancer. The method uses the alpha-toxin from Clostridium septicum to separate GPI-anchored glycoproteins for identification and optionally quantification. The GPI-APs so obtained may be used to raise antibodies for inclusion in an immunosorbent assay for the diagnosis or the monitoring of therapy of cancer in a patient.Type: ApplicationFiled: January 28, 2014Publication date: October 23, 2014Applicant: University of Georgia Research Foundation, Inc.Inventors: James Michael Pierce, Karen Lynn Abbott
-
Publication number: 20140308302Abstract: Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.Type: ApplicationFiled: May 29, 2014Publication date: October 16, 2014Inventors: Erwin R. BOGHAERT, Nitin K. DAMLE, Philip Ross HAMANN, Kiran KHANDKE, Arthur KUNZ, Kimberly A. MARQUETTE, Lioudmila TCHISTIAKOVA, Davinder GILL, Kodangattil R. SREEKUMAR
-
Publication number: 20140308264Abstract: Modified VEGF proteins that inhibit VEGF-mediated activation or proliferation of endothelial cells are disclosed. The analogs may be used to inhibit VEGF-mediated activation of endothelial cells in angiogenesis-associated diseases such as cancer, inflammatory diseases, eye diseases, and skin disorders.Type: ApplicationFiled: June 23, 2014Publication date: October 16, 2014Inventors: Mariusz W. Szkudlinski, Bruce D. Weintraub
-
Publication number: 20140309163Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.Type: ApplicationFiled: May 12, 2014Publication date: October 16, 2014Inventors: Sharon CLOAD, Linda ENGLE, Dasa LIPOVSEK, Malavi MADIREDDI, Ginger Chao RAKESTRAW, Joanna SWAIN, Wenjun ZHAO, Martin J. Corbett, Alexander T. Kozhich
-
Publication number: 20140308308Abstract: The present disclosure provides compositions and methods useful for treating HCMV infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more HCMV epitopes, such as, for example, from HCMV envelope glycoproteins gB and/or gH and/or tegument protein pp65. Among other things, the present invention encompasses the recognition that a combination of antigens (e.g., envelope glycoproteins and structural proteins) can lead to beneficial immune responses, for example that include both a humoral response (e.g., production of neutralizing antibodies) and a cellular response (e.g., T-cell activation).Type: ApplicationFiled: November 9, 2012Publication date: October 16, 2014Applicant: Variation Biotechnolgies, Inc.Inventors: David E. Anderson, Anne-Catherine Fluckiger
-
Patent number: 8859724Abstract: The invention relates to a bonding product suitable as a carrier for medicinal substances and to the compound derived therefrom that carries medicinal substances. The invention further relates to a process and device for preparing such bonding products and compounds. Further, the invention relates to a pharmaceutical composition containing such bonding products and compounds, and to the use thereof for preparing an infusible medicament for treating a disease.Type: GrantFiled: April 26, 2007Date of Patent: October 14, 2014Assignee: B. Braun Melsungen AGInventors: Bernd H. Meier, Nele Meier
-
Patent number: 8858951Abstract: The invention is directed to the use of (i) a first antigen corresponding to a target antigen of interest, together with (ii) a second antigen, corresponding to a modified form of the target antigen, whose rate of intracellular proteolytic degradation is increased, enhanced or otherwise elevated relative to the first antigen, in compositions and methods for inducing both humoral and cellular immunity in an individual. The ability to provide compositions, which are capable of inducing both host-protective antibody and cell-mediated immune responses, facilitates the generation of immunogenic compositions capable of combating, inter alia, conditions that have long latency periods and, therefore, benefit from the dual approach of prophylaxis and therapy in one delivery.Type: GrantFiled: April 18, 2002Date of Patent: October 14, 2014Assignee: The University of QueenslandInventor: Ian Hector Frazer
-
Patent number: 8859240Abstract: The present invention relates to the development of viral vectors expressing different immunogens from the West Nile Encephalitis Virus (WNV) or the Dengue virus which are able to induce protective humoral and cellular immune responses against WNV or Dengue virus infections. More specifically, the present invention relates to three (3) antigens from WNV (the secreted envelope glycoprotein (E), the heterodimer glycoproteins (pre-M-E) and the NSI protein) and from Dengue virus (the secreted envelope glycoprotein (e), the heterodimer glycoproteins (pre-m-e) and the nsl protein) and their use in vaccinal, therapeutic and diagnostic applications.Type: GrantFiled: June 2, 2009Date of Patent: October 14, 2014Assignees: Institut Pasteur, Centre National de la Recherche ScientifiqueInventors: Frédéric Tangy, Philippe Despres, Chantal Combredet, Marie Pascale Frenkiel
-
Publication number: 20140302618Abstract: Novel conjugates and immunogens derived from clozapine and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of clozapine in biological fluids.Type: ApplicationFiled: May 22, 2014Publication date: October 9, 2014Applicant: Saladax Biomedical Inc.Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Howard Sard, Christopher Spedaliere
-
Publication number: 20140302592Abstract: The present invention relates to a two-step method for the purification of divalent cation binding proteins with high yield and high purity on anion exchange resin materials, to divalent cation binding proteins obtainable by said method, and to a kit comprising means for carrying out said method.Type: ApplicationFiled: October 12, 2012Publication date: October 9, 2014Inventors: Artur Mitterer, Meinhard Hasslacher, Christian Fiedler
-
Publication number: 20140302523Abstract: The present invention includes compounds that are useful in perturbing or disrupting the function of a transmembrane or intracellular protein, whereby binding of a compound to the transmembrane or intracellular protein induces proteasomal degradation of the transmembrane or intracellular protein. The present invention further includes a method of inducing proteasomal degradation of a transmembrane or intracellular protein. The present invention further includes a method of identifying or validating a protein of interest as a therapeutic target for treatment of a disease state or condition.Type: ApplicationFiled: December 6, 2011Publication date: October 9, 2014Applicant: Yale UniversityInventors: Craig M. Crews, Hyun Seop Tae, Ashley R. Schneekloth, Taavi Neklesa, Thomas Sundberg
-
Publication number: 20140302489Abstract: The invention relates to a polypeptide of a protective antigenic determinant (PAD polypeptide) of porcine reproductive and respiratory syndrome virus (PRRSV) and nucleic acids encoding a PAD polypeptide. The PAD polypeptide and nucleic acids encoding a PAD polypeptide are useful in the development of antibodies directed to PAD, vaccines effective in providing protection against PRRSV infection, and diagnostic assays detecting the presence of PAD antibodies generated by a PAD-specific vaccine. The invention also discloses methods of generating antibodies to PAD, for vaccinating a pig to provide protection from PRRSV infections, a method of preparing the vaccine, a method of treating PRRSV infections in a pig, and a method of detecting antibodies to PAD of PRRSV.Type: ApplicationFiled: May 15, 2014Publication date: October 9, 2014Inventors: Delbert L. Harris, Matthew M. Erdman
-
Publication number: 20140302080Abstract: The invention features stabilized human immunodeficiency virus (HIV) envelope (Env) trimers. The invention also features vaccines, nucleic acids, and vectors to deliver and/or facilitate production of the stabilized HIV Env trimers. In addition, the invention features methods of making and using the stabilized HIV Env trimers of the invention.Type: ApplicationFiled: January 7, 2014Publication date: October 9, 2014Applicant: Beth Israel Deaconess Medical Center, Inc.Inventors: Dan H. BAROUCH, Joseph Patrick Nkolola
-
Publication number: 20140302527Abstract: This invention relates to a target-specific probe containing a ferritin fusion protein and a targeting agent, a target-specific imaging probe containing a labeling agent coupled to the target-specific probe, and a detection method or detection kit of a biomarker using these probes.Type: ApplicationFiled: May 22, 2013Publication date: October 9, 2014Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGYInventors: Kwan-Hyi LEE, Jong-Hoon Choi, Mintai Peter Hwang, Yu-Chan Kim, Jong-Wook Lee, Hyun-Kwang Seok
-
Patent number: 8853354Abstract: A polyion complex (PIC) or a PIC nanoparticle that may be easily prepared, and that is finally disappeared in vivo due to its suitable biodegradability while exhibiting high stability in vivo, an immunotherapy agent comprising the PIC nanoparticle to which various antigen proteins or peptides may be easily conjugated or incorporated and/or which may be easily mixed with the antigen proteins or peptides, as well as a process for preparing thereof are provided. Specifically, a polyion complex (PIC) comprising a hydrophobized poly(acidic amino acid) and a basic polypeptide, a nanoparticle thereof having a particle shape, an immunotherapy agent comprising the PIC nanoparticle, as well as a process for preparing the PIC, comprising steps of introducing a hydrophobic amino acid to a poly(acidic amino acid) to prepare a hydrophobized poly(acidic amino acid), and dissolving the hydrophobized poly(acidic amino acid) prepared to a buffer, and it is mixed with a basic polypeptide dissolved in a buffer.Type: GrantFiled: March 26, 2010Date of Patent: October 7, 2014Assignee: Kagoshima UniversityInventors: Masanori Baba, Tomofumi Uto, Mitsuru Akashi, Takami Akagi, Chikateru Nozaki, Kazuyoshi Kaminaka
-
Patent number: 8853370Abstract: The present invention provides a method for manufacturing a glycoprotein having a human-type sugar chain comprising a step in which transformed plant cell is obtained by introducing to a plant cell the gene of glycosyltransfetase and the gene of an exogenous glycoprotein, and a step in which the obtained transformed plant cell is cultivated.Type: GrantFiled: July 11, 2012Date of Patent: October 7, 2014Assignee: Phyton Holdings, LLCInventors: Tatsuji Seki, Kazuhito Fujiyama
-
Patent number: 8853154Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.Type: GrantFiled: September 12, 2013Date of Patent: October 7, 2014Assignee: Bristol-Myers Squibb CompanyInventors: Sharon Cload, Linda Engle, Dasa Lipovsek, Malavi Madireddi, Ginger Chao Rakestraw, Joanna Swain, Wenjun Zhao, Hui Wei, Aaron P. Yamniuk, Vidhyashankar Ramamurthy, Alexander T. Kozhich, Martin J. Corbett, Stanley Richard Krystek, Jr.
-
Publication number: 20140294930Abstract: In alternative embodiments, the invention provides vaccines, pharmaceutical compounds and formulations for diagnosing, preventing, treating or ameliorating Group A Streptococcus (GAS), Group C Streptococcus (GCS), or Group A Streptococcus (GGS), infections, or other pathogenic Streptococcus infections. In alternative embodiments, the invention provides compositions such as diagnostic tests, assays, immunoassays and test strips, and methods, for detecting or diagnosing the presence of a Streptococcal infection, e.g., Group A Streptococcus (GAS), Group C Streptococcus (GCS), or Group A Streptococcus (GGS), infections, or other pathogenic Streptococcus infections.Type: ApplicationFiled: August 3, 2012Publication date: October 2, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Victor Nizet, Nina van Sorge
-
Publication number: 20140294757Abstract: A method for preserving a polypeptide comprising: (a) providing an aqueous solution of (i) the polypeptide, (ii) one or more sugars, and (iii) a compound of formula (I) or a physiologically acceptable salt or ester thereof and/or a compound of formula (II) or a physiologically acceptable salt or ester thereof; and (b) drying the solution to form a composition incorporating the polypeptide.Type: ApplicationFiled: October 5, 2012Publication date: October 2, 2014Applicant: Stabilitech Ltd.Inventors: Jeffrey Drew, David Thomas Woodward, Stephen Ward
-
Publication number: 20140298508Abstract: The present invention is directed to alpha-mannosidase sequences from plants and the use thereof, especially genomic nucleotide sequences containing the regulatory elements controlling their expression, intron and exon sequences and polynucleotide sequences coding for alpha-mannosidase enzymes. Such plants with modified alpha-mannosidase activity can be used for the production of glycoproteins having an altered saccharide composition of great benefit. The present invention also relates to the use of these alpha-mannosidase enzymes for hydrolyzing mannoses.Type: ApplicationFiled: December 23, 2011Publication date: October 2, 2014Applicant: PHILIP MORRIS PRODUCTS S.A.Inventors: Nikolai Valeryevitch Ivanov, Prisca Camponini, Dionisius Florack, Karen Oishi
-
Publication number: 20140295521Abstract: A new use of a molecule comprising at least one moiety which is a biologically active protein and at least one moiety capable of binding to a serum albumin of a mammal is provided, for preparation of a medicament which elicits no or a reduced immune response upon administration to the mammal, as compared to the immune response elicited upon administration to the mammal of the biologically active protein per se. Also provided is a method of reducing or eliminating the immune response elicited upon administration of a biologically active protein to a human or non-human mammal, which comprises coupling the polypeptide to at least one moiety capable of binding to a serum albumin of the mammal.Type: ApplicationFiled: January 21, 2014Publication date: October 2, 2014Applicant: AFFIBODY ABInventor: Nina Herne
-
Publication number: 20140294762Abstract: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.Type: ApplicationFiled: April 7, 2014Publication date: October 2, 2014Applicant: Novo Nordisk A/SInventors: Shawn DeFrees, David A. Zopf, Robert J. Bayer, David James Hakes, Caryn L. Bowe, Xi Chen
-
Patent number: 8846342Abstract: The invention is directed to bioconjugate vaccines comprising N-glycosylated proteins. Further, the present invention is directed to a recombinant prokaryotic biosynthetic system comprising nucleic acids encoding an epimerase that synthesizes an oligo- or polysaccharide having N-acetylgalactosamine at the reducing terminus. The invention is further directed to N-glycosylated proteins containing an oligo- or polysaccharide having N-acetylgalactosamine at the reducing terminus and an expression system and methods for producing such N-glycosylated proteins.Type: GrantFiled: November 16, 2010Date of Patent: September 30, 2014Assignee: GlycoVaxyn AGInventors: Michael Wacker, Charles Waechter
-
Publication number: 20140287412Abstract: The present invention provides a method for detecting ACF by analyzing a test region of large intestine tissue at the molecular level. Namely, the present invention relates to a method for detecting aberrant crypt foci (ACF) that comprises detecting an ACF detection marker in a test region of large intestine tissue, by using one or more types of molecules for which ACF-specific expression increases as the ACF detection marker, the molecule being selected from the group consisting of SLC2a1, and SLC7a7; an ACF detection marker for detecting the ACF in human-derived large intestine tissue, that is SLC2a1, or SLC7a7; and, a method for evaluating risk of colorectal cancer and colorectal adenoma in subjects based on the results of detecting ACF in a test region of large intestine tissue of the subjects using the aforementioned ACF detection method.Type: ApplicationFiled: June 6, 2014Publication date: September 25, 2014Applicants: OLYMPUS CORPORATION, THE UNIVERSITY OF TOKUSHIMAInventors: Fumiko Ono, Yoko Horino, Tetsuji Takayama, Naoki Muguruma, Koichi Okamoto
-
Publication number: 20140286983Abstract: Described herein are dengue virus E-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes associated with immune enhancement. The disclosed dengue virus E-glycoproteins optionally further include mutations that introduce a strong CD4 T cell epitope. The disclosed E-glycoprotein polypeptides, or nucleic acid molecules encoding the polypeptides, can be used, for example, in monovalent or tetravalent vaccines against dengue virus.Type: ApplicationFiled: October 18, 2012Publication date: September 25, 2014Inventors: Gwong-Jen J. Chang, Wayne D. Crill, Holly R. Hughes, Brent S. Davis